logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics serves its defence in legal spat with Alnylam Pharmaceuticals

Silence continues to regard these actions from all parties as simply the "normal course of business" at the commencement of litigation

Patent licence
Silence is a leader in the field of RNA therapeutics for the treatment of serious diseases with unmet medical need

Silence Therapeutics PLC (LON:SLN) has served its defence in the legal actions initiated against it by Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) and The Medicines Company.

The companies have been engaged in a dispute over patents, with Silence citing Alnylam, a US drugs company valued at US$12.5bn, as one of the companies it believed had been using its technology in drugs that “silence” genes, prompting Alnylam to take legal action to have Silence’s European patent EP 2 258 847B revoked in the UK.

READ: Silence Therapeutics says Alnylam legal response just the "normal course of business"

Alnylam’s petition included declarations of non-infringement of EP 2 258 847B by certain Alnylam products.

Silence has now counterclaimed for threatened infringement of the Silence European patent EP 2 258 847B by Alnylam UK and The Medicines Company; if successful, products including patisiran, fitusiran, givosiran and inclisiran will be found to infringe EP 2 258 847B.

In its stock market announcement, Silence also noted that Alnylam and The Medicines Company are yet to serve their respective defences in relation to the earlier served action brought by Silence for a declaration as to its entitlement to claim supplementary protection certificates protection on products containing the above-named active substances.

Supplementary protection certificates, as the name suggests, extend the protection of certain active ingredients in drugs.

READ: Silence Therapeutics granted yet more US patents for its innovative chemical modification

"We continue to believe that our fundamental chemical modification technology is core foundational innovation for today's RNAi sector, and that therefore those companies using such modification technology within the scope of our intellectual property (IP) will require a licence," said Ali Mortazavi, chief executive officer of Silence Therapeutics.

 

Quick facts: Silence Therapeutics PLC

Price: 530 GBX

AIM:SLN
Market: AIM
Market Cap: £415.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Silence Therapeutics CEO talks recent RNAi deals and updates on critical...

Silence Therapeutics PLC's (LON:SLN) David Solomon discusses with Proactive London's Andrew Scott the recent deal between Novartis and The Medicines Company for its asset - the RNAi project inclisiran. Solomon also updates on their lead candidate, SLN124, which is being developed to treat...

2 weeks, 2 days ago

RNS

Additional Listing

2 weeks, 3 days ago

Additional Listing

3 weeks, 1 day ago

Holding(s) in Company

on 13/11/19

Additional Listing

on 30/10/19

Additional Listing

on 25/10/19

Holding(s) in Company

on 14/10/19

Holdings in Company

on 7/10/19

2 min read